Mäcke HR - Search Results

1

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC. Ginj M, et al. Among authors: macke hr. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41. doi: 10.1073/pnas.0607761103. Epub 2006 Oct 20. Proc Natl Acad Sci U S A. 2006. PMID: 17056720 Free PMC article.

2

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.

Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, Reubi JC, Mäcke HR. Eisenwiener KP, et al. Among authors: macke hr. Bioconjug Chem. 2002 May-Jun;13(3):530-41. doi: 10.1021/bc010074f. Bioconjug Chem. 2002. PMID: 12009943 Free article.

3

A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors.

Reubi JC, Eisenwiener KP, Rink H, Waser B, Mäcke HR. Reubi JC, et al. Among authors: macke hr. Eur J Pharmacol. 2002 Dec 5;456(1-3):45-9. doi: 10.1016/s0014-2999(02)02651-1. Eur J Pharmacol. 2002. PMID: 12450568

4

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC. Wild D, et al. Among authors: macke hr. Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47. doi: 10.1007/s00259-003-1255-5. Epub 2003 Aug 21. Eur J Nucl Med Mol Imaging. 2003. PMID: 12937948

5

68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.

Wild D, Mäcke HR, Waser B, Reubi JC, Ginj M, Rasch H, Müller-Brand J, Hofmann M. Wild D, et al. Among authors: macke hr. Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):724. doi: 10.1007/s00259-004-1697-4. Eur J Nucl Med Mol Imaging. 2005. PMID: 15551131 No abstract available.

6

Candidates for peptide receptor radiotherapy today and in the future.

Reubi JC, Mäcke HR, Krenning EP. Reubi JC, et al. Among authors: macke hr. J Nucl Med. 2005 Jan;46 Suppl 1:67S-75S. J Nucl Med. 2005. PMID: 15653654 Free article. Review.

7

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Mäcke HR. Wild D, et al. Among authors: macke hr. J Nucl Med. 2006 Dec;47(12):2025-33. J Nucl Med. 2006. PMID: 17138746 Free article.

8

Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC, Schonbrunn A. Cescato R, et al. Among authors: macke hr. Mol Endocrinol. 2010 Jan;24(1):240-9. doi: 10.1210/me.2009-0321. Epub 2009 Nov 12. Mol Endocrinol. 2010. PMID: 19910453 Free PMC article.

9

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.

Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Reubi JC, et al. Among authors: macke hr. Eur J Nucl Med. 2000 Mar;27(3):273-82. doi: 10.1007/s002590050034. Eur J Nucl Med. 2000. PMID: 10774879

10

Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers.

Reubi JC, Waser B, Mäcke H, Rivier J. Reubi JC, et al. J Nucl Med. 2017 Feb;58(2):300-306. doi: 10.2967/jnumed.116.177733. Epub 2016 Aug 25. J Nucl Med. 2017. PMID: 27561878 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters